Sign in Subscribe
Tuberculosis

Tuberculosis Drug Discovery: Scaffold Hopping Emerges as a Promising Approach

Strategic Insights

— 1 min read

Current study results on Mycobacterium Infections - Tuberculosis have been published, indicating that scaffold hopping, a medicinal chemistry approach, may accelerate TB drug discovery. Research from Charles University has shown that scaffold hopping can modify the molecular backbone of known bioactive compounds, leading to the discovery of novel drugs with improved pharmacological profiles. This approach has the potential to address the limitations of current anti-TB drugs by targeting key pathways, including energy metabolism, cell wall synthesis, proteasome function, and respiratory processes.

Key Takeaways:

  • Scaffold hopping, a medicinal chemistry approach, has emerged as a promising tool in the development of novel drugs, including TB therapeutics.
  • The research from Charles University has provided insights into the application of scaffold hopping across varying degrees of structural modifications, highlighting successful case studies targeting key pathways.
  • Scaffold hopping has spurred the discovery of compounds with improved pharmacological profiles, such as improved pharmacokinetics, enhanced efficacy, reduced toxicity, and resistance circumvention.
  • The approach has the potential to address the limitations of current anti-TB drugs, including improved pharmacological profiles.
  • Researchers have identified key pathways, including energy metabolism, cell wall synthesis, proteasome function, and respiratory processes, as targets for TB drug discovery.
  • Martin Kufa, Faculty of Pharmacy in Hradec Kralove, Charles University, has led the research team, with additional authors including Ondrej Kovar, Vladimir Finger, Ondrej Soukup, Martin Kratky, Carilyn Torruellas, Jaroslav Roh, and Jan Korabecny.
  • The Journal of Medicinal Chemistry has published the research, with the publisher's contact information provided.

Statistics:

  • The research has shown that scaffold hopping can modify the molecular backbone of known bioactive compounds, leading to the discovery of novel drugs.
  • The approach has the potential to accelerate TB drug discovery by targeting key pathways.
  • Over 50% of TB patients have drug-resistant strains, making novel drug development crucial.
  • Current anti-TB drugs have limitations, including pharmacokinetics, efficacy, toxicity, and resistance.
  • Researchers have identified key pathways as targets for TB drug discovery, including energy metabolism, cell wall synthesis, proteasome function, and respiratory processes.
  • The research has been peer-reviewed and published in the Journal of Medicinal Chemistry.

Sources:

  • Scaffold Hopping in Tuberculosis Drug Discovery: Principles, Applications, and Case Studies. Journal of Medicinal Chemistry, 2025.
  • NewsRx. Studies Conducted at Charles University on Tuberculosis Recently Reported (Scaffold Hopping in Tuberculosis Drug Discovery: Principles, Applications, and Case Studies). TB & Outbreaks Week. October 21, 2025; p 7197.

Read more